Sodium–glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction
Luca Monzo, Ilaria Ferrari, F Cicogna, Claudia Tota, Leonardo Calò
Topics & Concepts
DapagliflozinEmpagliflozinMedicineHeart failureEjection fractionInternal medicineDiabetes mellitusClinical trialPopulationCardiologyType 2 diabetesEndocrinologyEnvironmental healthDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsPancreatic function and diabetes